BioCentury
ARTICLE | Clinical News

Oral solithromycin: Additional Phase III data

May 11, 2015 7:00 AM UTC

Data from a predefined subgroup of patients ages >=75 with moderate to severe CABP in the double-blind, international Phase III Solitaire-Oral trial showed that once-daily oral solithromycin for 5 days led to an early clinical response at 72 hours after initiation of therapy, the primary endpoint, in 83.9% of patients vs. 69.8% of patients receiving oral moxifloxacin for 7 days. An early clinical response was defined as an improvement in >=2 of 4 symptoms -- cough, shortness of breath, chest pain and sputum production -- without worsening of any. Patients received 800 mg solithromycin on day 1 and 400 mg thereafter. Data were presented at the European Society of Clinical Microbiology and Infectious Disease meeting in Copenhagen. ...